Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D G Heppner

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
The New England Journal of Medicine|January 9, 1997
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation GroupJ A Stoute, M Slaoui, D G Heppner, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 2, 2001
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquineA Brockman, R N Price, M van Vugt, et al.
The Journal of Infectious Diseases|June 1, 1995
Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccineD M Gordon, T W McGovern, U Krzych, et al.
The American Journal of Tropical Medicine and Hygiene|February 6, 1998
Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malariaA Sabchareon, P Attanath, P Chanthavanich, et al.
The American Journal of Tropical Medicine and Hygiene|May 1, 1997
Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast AsiaF Nosten, C Luxemburger, D E Kyle, et al.
Vaccine|June 12, 2003
CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based MontanidesC Hirunpetcharat, J Wipasa, S Sakkhachornphop, et al.
Parasitology|January 1, 1995
Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy studyW R Ballou, J Blood, T Chongsuphajaissidhi, et al.
Lancet (London, England)|June 4, 1994
Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparumR A Kuschner, D G Heppner, S L Andersen, et al.
Lancet (London, England)|September 14, 1996
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial GroupF Nosten, C Luxemburger, D E Kyle, et al.
The American Journal of Tropical Medicine and Hygiene|July 1, 1996
Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United StatesD M Gordon, P E Duffy, D G Heppner, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
The New England Journal of Medicine|January 9, 1997
A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation GroupJ A Stoute, M Slaoui, D G Heppner, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|January 2, 2001
Plasmodium falciparum antimalarial drug susceptibility on the north-western border of Thailand during five years of extensive use of artesunate-mefloquineA Brockman, R N Price, M van Vugt, et al.
The Journal of Infectious Diseases|June 1, 1995
Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccineD M Gordon, T W McGovern, U Krzych, et al.
The American Journal of Tropical Medicine and Hygiene|February 6, 1998
Comparative clinical trial of artesunate suppositories and oral artesunate in combination with mefloquine in the treatment of children with acute falciparum malariaA Sabchareon, P Attanath, P Chanthavanich, et al.
The American Journal of Tropical Medicine and Hygiene|May 1, 1997
Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast AsiaF Nosten, C Luxemburger, D E Kyle, et al.
Vaccine|June 12, 2003
CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based MontanidesC Hirunpetcharat, J Wipasa, S Sakkhachornphop, et al.
Parasitology|January 1, 1995
Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy studyW R Ballou, J Blood, T Chongsuphajaissidhi, et al.
Lancet (London, England)|June 4, 1994
Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparumR A Kuschner, D G Heppner, S L Andersen, et al.
Lancet (London, England)|September 14, 1996
Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial GroupF Nosten, C Luxemburger, D E Kyle, et al.
The American Journal of Tropical Medicine and Hygiene|July 1, 1996
Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United StatesD M Gordon, P E Duffy, D G Heppner, et al.
Pageof 4